Ono picked up Romvimza—previously known by its active ingredient vimseltinib—from its $2.4 billion acquisition of Deciphera ...
TGCT is a rare, non-cancerous tumour affecting the joints, tendons, or joint tissue. It is linked to a CSF1 gene mutation ...
A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives ...
In the Japan business unit, sales of Lixiana, a direct oral anticoagulant; Tarlige analgesic; and ENHERTU, an anti-cancer agent increased as did the sales of Daiichi Sankyo Healthcare, while again ...
Drugmaker Daiichi Sankyo has risen the most in five months after its novel breast cancer treatment won U.S. approval, a milestone in the company’s efforts to turn it into a widely used blockbuster.
Daiichi Sankyo, an innovative global healthcare company, has established a state-of-the-art research laboratory in San Diego, California, US, dedicated to the development of robotics, automation and ...
A new European survey sponsored by AstraZeneca (AZ) and Daiichi Sankyo has revealed widespread misconceptions about breast cancer and metastatic cases of the disease. The online questionnaire gathered ...
AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) has been approved by the US Food and Drug Administration (FDA) to treat a subset of breast cancer patients. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback